Blenrep shows overall survival benefit in head-to-head DREAMM-7 …
1 day ago · The DREAMM-7 phase III clinical trial is a multicentre, open-label, randomised trial evaluating the efficacy and safety of belantamab mafodotin in combination with BorDex …
Belantamab Mafodotin, Bortezomib, and Dexamethasone for …
Jun 1, 2024 · B-cell maturation antigen (BCMA) is an established target for the treatment of multiple myeloma. 6 Belantamab mafodotin is a BCMA-targeting antibody–drug conjugate with …
GSK hails survival data with revived myeloma drug Blenrep
17 hours ago · GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an increase in overall survival (OS) with the drug …
from the DREAMM-7 trial underscore the potential for this Blenrep combination to extend the lives of patients with relapsed/refractory multiple myeloma. This is a statistically significant and …
Benefit of Belantamab Mafodotin–Based Regimen Supported in …
Mar 10, 2024 · DREAMM-7 enrolled 494 patients with multiple myeloma previously treated with at least one prior line of therapy; they were randomly assigned to receive BVd or DVd. …
Results from the randomized phase III DREAMM-7 study of ...
DREAMM-7 (NCT04246047) is a global, randomized, open-label, phase III head-to-head trial evaluating the efficacy and safety of BVd triplet vs SoC triplet, DVd, in patients (pts) with …
DREAMM-7 phase III trial shows Blenrep combination ... - GSK
Feb 5, 2024 · The DREAMM-7 phase III clinical trial is a multicentre, open-label, randomised trial evaluating the efficacy and safety of belantamab mafodotin in combination with bortezomib …
GSK Reports Positive Headline Results From DREAMM-7 Phase III …
20 hours ago · GSK plc (GSK,GSK.L), on Thursday, announced positive headline results from a planned interim analysis of the DREAMM-7 head-to-head phase III trial evaluating Blenrep …
GSK's ADC Blenrep delivers survival win against J&J's Darzalex
13 hours ago · Previously, DREAMM-7 had met its primary endpoint of progression-free survival, showing the Blenrep-Vd combo significantly slashed the risk of progression or death by 59% …
GSK Reports Positive Headline Results From DREAMM-7 Phase III …
20 hours ago · RTTNews. Nov. 14, 2024, 02:30 AM. (RTTNews) - GSK plc (GSK, GSK.L), on Thursday, announced positive headline results from a planned interim analysis of the …